Lantern Pharma (LTRN) Projected to Post Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is anticipated to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:00 AM ET.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.10.

Lantern Pharma Price Performance

LTRN opened at $2.14 on Thursday. The firm has a market cap of $24.20 million, a P/E ratio of -1.36 and a beta of 2.10. Lantern Pharma has a 1-year low of $1.11 and a 1-year high of $5.74. The company has a 50 day simple moving average of $2.27 and a two-hundred day simple moving average of $2.99.

Hedge Funds Weigh In On Lantern Pharma

A number of hedge funds have recently modified their holdings of LTRN. Cetera Investment Advisers bought a new position in shares of Lantern Pharma in the fourth quarter worth approximately $37,000. XTX Topco Ltd bought a new position in shares of Lantern Pharma in the second quarter worth approximately $40,000. CIBC Private Wealth Group LLC bought a new position in shares of Lantern Pharma in the fourth quarter worth approximately $47,000. Two Sigma Investments LP bought a new position in shares of Lantern Pharma in the third quarter worth approximately $70,000. Finally, Susquehanna International Group LLP bought a new position in shares of Lantern Pharma in the third quarter worth approximately $170,000. 28.62% of the stock is currently owned by institutional investors.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.